Hot Features
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It... Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 1.32 | 1.32 | 1.32 | 2000 | 1.32 | CS |
| 4 | -0.55 | -29.4117647059 | 1.87 | 1.87 | 1.32 | 4750 | 1.59631579 | CS |
| 12 | -0.62 | -31.9587628866 | 1.94 | 2.5 | 1.32 | 2500 | 1.98149021 | CS |
| 26 | -0.42 | -24.1379310345 | 1.74 | 2.5 | 1.32 | 3100 | 1.87003704 | CS |
| 52 | 0.065 | 5.17928286853 | 1.255 | 2.5 | 1.145 | 2579 | 1.69983593 | CS |
| 156 | 1.1219 | 566.330136295 | 0.1981 | 2.5 | 0.1402 | 3453 | 0.94696824 | CS |
| 260 | 1.27 | 2540 | 0.05 | 2.5 | 0.0021 | 3170 | 0.8372606 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.